Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $352
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $340 to $352.
August 04, 2023 | 11:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Vertex Pharmaceuticals and raises the price target from $340 to $352.
The raised price target by Morgan Stanley indicates a positive outlook for Vertex Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100